PMID- 38245394
OWN - NLM
STAT- MEDLINE
DCOM- 20240311
LR  - 20240311
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 33
IP  - 2
DP  - 2024 Feb
TI  - Clinical Outcomes Following Transcatheter Mitral Valve-in-Valve Replacement Using 
      a Meril Myval Transcatheter Heart Valve.
PG  - 222-229
LID - S1443-9506(23)04445-1 [pii]
LID - 10.1016/j.hlc.2023.11.011 [doi]
AB  - AIM: Transcatheter mitral valve-in-valve (TMViV) replacement for degenerated 
      surgically implanted bioprosthetic valves has been described by both transseptal 
      and transapical approaches. The balloon-expandable Myval transcatheter valve 
      (Meril Life Sciences, Vapi, India) is commonly used for transcatheter 
      valve-in-valve procedures in India. This study aimed to report in-hospital, 
      30-day, and 1-year outcomes of Myval patients who underwent TMViV in a single 
      tertiary care centre in India. METHODS: Symptomatic patients with surgical 
      bioprosthetic mitral valve failure with New York Heart Association (NYHA) class 
      III-IV symptoms, despite optimal medical therapy and high or very high risk for 
      redo surgery, were assigned to TMViV following heart team discussions. Data were 
      retrospectively collected and outcomes assessed. RESULTS: Twenty patients were 
      treated, with mean age 64.4 years, 60% were female, and mean Society of Thoracic 
      Surgeons (STS) predicted risk of operative mortality score was 8.1. The failure 
      mechanism was combined stenosis and regurgitation in 60% of patients. Technical 
      success was achieved in 100% of patients. The mean postprocedure and 30-day 
      gradients were 4.6+/-2.7 and 6.3+/-2.1, respectively. None of them had significant 
      valvular or paravalvular leaks or left ventricular outflow tract obstruction. 
      All-cause mortality at 1 year was 10%, and all survivors were in New York Heart 
      Association (NYHA) class I or II. CONCLUSION: TMViV replacement with a Meril 
      Myval can be safely performed with high technical success, and low 30-day and 
      1-year mortality.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Sankardas, Mullasari Ajit
AU  - Sankardas MA
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India. 
      Electronic address: sulu_ajit57@yahoo.co.in.
FAU - Subban, Vijayakumar
AU  - Subban V
AD  - Department of Cardiology, Apollo Hospitals, Chennai, India.
FAU - Kothandam, Sivakumar
AU  - Kothandam S
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India.
FAU - Chopra, Aashish
AU  - Chopra A
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India.
FAU - Kalidoss, Latchumanadhas
AU  - Kalidoss L
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India.
FAU - Udhayakumar, Kalaichelvan
AU  - Udhayakumar K
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India.
FAU - Sollimuthu, Ramkumar
AU  - Sollimuthu R
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India.
FAU - Chidambaram, Kumar
AU  - Chidambaram K
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India.
FAU - Anandan, Harini
AU  - Anandan H
AD  - Department of Anaesthesiology, The Madras Medical Mission, Chennai, India.
FAU - Rao, Ravinder Singh
AU  - Rao RS
AD  - Heart Center, Rajasthan Hospital, Jaipur, India.
LA  - eng
PT  - Journal Article
DEP - 20240119
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
SB  - IM
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - Male
MH  - Mitral Valve/diagnostic imaging/surgery
MH  - *Heart Valve Prosthesis Implantation/methods
MH  - *Heart Valve Prosthesis
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Cardiac Catheterization/methods
MH  - Prosthesis Design
OTO - NOTNLM
OT  - Degenerative mitral bioprosthesis
OT  - Meril Myval
OT  - Transcatheter mitral valve-in-valve
EDAT- 2024/01/21 00:42
MHDA- 2024/03/11 06:42
CRDT- 2024/01/20 21:53
PHST- 2023/02/10 00:00 [received]
PHST- 2023/10/12 00:00 [revised]
PHST- 2023/11/12 00:00 [accepted]
PHST- 2024/03/11 06:42 [medline]
PHST- 2024/01/21 00:42 [pubmed]
PHST- 2024/01/20 21:53 [entrez]
AID - S1443-9506(23)04445-1 [pii]
AID - 10.1016/j.hlc.2023.11.011 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2024 Feb;33(2):222-229. doi: 10.1016/j.hlc.2023.11.011. Epub 
      2024 Jan 19.